Subscribe to the newsletter:

For too long, accessing catalytic funding has been a challenge for medicines discovery start-ups focused in areas of clinical unmet need. To combat this, Medicines Discovery Catapult (MDC) and We Share Ventures (We Share) have launched an innovative new funding programme. The programme will provide grants of up to €300,000 to at least two early-stage medicines discovery startups focused on the development of new treatments for psychiatric disorders, hearing loss and tinnitus, or infections associated with cystic fibrosis (CF). Underpinned by We Share’s share-it-forward principle, successful start-ups will share their success with future innovators through a revolving funding mechanism.

Creating real impact is at the core of both MDC and We Share. This is why We Share is bringing its innovative impact-driven revolving funding model together with MDC’s Syndicate programme to give promising start-ups in the medicine discovery space, access to long-term capital in the early phases of their growth. Through its Syndicate programme, MDC has created and supported world-class medicines discovery consortia in areas of patient need; bringing together leading experts and accelerating research efforts. Through Syndicates, MDC can support emerging innovators with access to knowledge, expertise and capabilities in psychiatry, hearing and CF infections.

The patient centric design of the MDC X We Share Funding Programme is incredibly important. Patients will play a key role in the due diligence process, assisting in selecting the start-ups to fund. This is integral to ensure that the programme is addressing well-defined patient needs and funding companies selected by patients, for patients. For We Share, this collaboration is an opportunity to help more innovators survive the valley of death, support more solutions to address patient needs and make philanthropic giving more dynamic by revolving the funding.


Be inspired by cutting edge technologies from all over the world and stay up to date with the latest opportunities for startups.

There are still 2 weeks left until the application deadline (31.12.21). Are you an early-stage medicines discovery start-up based in Europe that is hoping to create impact for patients in any of the three focus areas (psychiatry, hearing, CF infections)? Check out the website for more details and to apply now: